Clinical Trial Update: Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients [Phase 3]

View source ↗

Summary

A Phase 3 study (Panther) compares biweekly and tailored EC-T chemotherapy against three-weekly FEC-T in breast cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Epirubicin (epirubicin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Karolinska University Hospital | Conditions: Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING